Colistin Methanesulfonate (sodium salt)
(Synonyms: 粘杆菌素甲基磺酸钠,Colimycin M,Polymyxin E sodium methanesulfonate) 目录号 : GC12613A mixture of colistins A and B
Cas No.:8068-28-8
Sample solution is provided at 25 µL, 10mM.
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Colistin methanesulfonate is an inactive prodrug of colistin (also known as polymyxin E), which is an antibiotic with effect against most Gram-negative bacteria, but also causes nephro- and neurotoxicity [1]. Colistin is produced by certain strains of the bacteria Paenibacillus polymyxa, and belongs to the class of polypeptide antibiotics known as polymyxins.
In Vitro: Studying the time-kill kinetics of Colistin methanesulfonate against a type culture of pseudomonas aeruginosa found that 8.0 or 32 mg/l Colistin methanesulfonate began killing at approximately 90 or 30 min, and the mean AUC0-240 values were 186.3±6.0 and 90.4±4.1, respectively [2]. Besides, by investigation among mucoid and nonmucoid strains of Pseudomonas aeruginosa isolated from patients with cystic fibrosis, Colistin methanesulfonate was found to require a concentration of 16 times the MIC to achieve complete killing within 24 h [3].
In Vivo: no data available.
Clinical trial: no data available.
References:
[1] Nation R L, Li J. Colistin in the 21st century.[J]. Current Opinion in Infectious Diseases, 2009, 22(6): 535-543.
[2] Bergen P J, Li J, Rayner C R, et al. Colistin methanesulfonate is an inactive prodrug of colistin against Pseudomonas aeruginosa.[J]. Antimicrobial Agents and Chemotherapy, 2006, 50(6): 1953-1958.
[3] Li J, Turnidge J D, Milne R W, et al. In Vitro Pharmacodynamic Properties of Colistin and Colistin Methanesulfonate against Pseudomonas aeruginosaIsolates from Patients with Cystic Fibrosis[J]. Antimicrobial Agents and Chemotherapy, 2001, 45(3): 781-785.
Cas No. | 8068-28-8 | SDF | |
别名 | 粘杆菌素甲基磺酸钠,Colimycin M,Polymyxin E sodium methanesulfonate | ||
化学名 | sodium (Z)-N-((6Z,9Z)-7,10-dihydroxy-8-(1-hydroxyethyl)-5-((Z)-oxido(((1Z,4E,7Z,10Z,13Z,16Z,19Z)-2,5,11,14-tetrahydroxy-3-(1-hydroxyethyl)-12,15-diisobutyl-8,17,20-trioxido-6,9,18-tris(2-((sulfomethyl)amino)ethyl)-1,4,7,10,13,16,19-heptaazacyclotricosa-1, | ||
Canonical SMILES | CCC(CCCC/C([O-])=N/C(/C(O)=N/C(/C(O)=N/C(/C([O-])=N/C(/C([O-])=N/C(/C([O-])=N/C(/C(O)=N/C(/C(O)=N/C(/C([O-])=N/C(/C(O)=N\1)CCNCS(O)(=O)=O)CCNCS(O)(=O)=O)CC(C)C)CC(C)C)CCNCS(O)(=O)=O)CC/N=C(O)/C1C(O)C)CCNCS(O)(=O)=O)C(O)C)CCNCS(O)(=O)=O)C.[Na+].[Na+].[Na+] | ||
分子式 | C58H105N16O28S5 • 5Na | 分子量 | 1749.8 |
溶解度 | ≥ 53.9mg/mL in Water | 储存条件 | 4°C, protect from light |
General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。 为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。 |
||
Shipping Condition | 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。 |
制备储备液 | |||
1 mg | 5 mg | 10 mg | |
1 mM | 0.5715 mL | 2.8575 mL | 5.7149 mL |
5 mM | 0.1143 mL | 0.5715 mL | 1.143 mL |
10 mM | 0.0571 mL | 0.2857 mL | 0.5715 mL |
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量) | ||||||||||
给药剂量 | mg/kg | 动物平均体重 | g | 每只动物给药体积 | ul | 动物数量 | 只 | |||
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方) | ||||||||||
% DMSO % % Tween 80 % saline | ||||||||||
计算重置 |
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL saline,混匀澄清。
1. 首先保证母液是澄清的;
2.
一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。